Silencing of LCN2 expression in the highly aggressive breast cancer cell line MDA-MB-231 has resulted into a diminished mesenchymal transition that has further confirmed the involvement of LCN2 in promoting EMT [249]. This evidence concerns the gene LCN2 and breast carcinoma.